Company Overview and News


Add BOTHE
to your dashboard

Headline News

Takeda's Offer On Tigenix - Good Deal Or Not?

2018-01-12 seekingalpha
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.

Bone Therapeutics: Deeply Undervalued Early Stage Biotech

2017-10-31 seekingalpha
A shot on three multibillion-dollar markets with highly unmet medical needs and very little competition (in two of the three markets). (24-3)

The Alliance for Regenerative Medicine Announces Presenting Companies at 2017 Cell & Gene Meeting on the Mesa

2017-07-19 marketwired
WASHINGTON, DC--(Marketwired - Jul 19, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017. (0-1)

The Alliance for Regenerative Medicine Releases Agenda for Fifth Annual Cell & Gene Therapy Investor Day

2017-04-06 marketwired
WASHINGTON, DC--(Marketwired - Apr 6, 2017) -  The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its upcoming fifth annual Cell & Gene Therapy Investor Day, taking place April 27, 2017 in Boston, MA. This event, co-hosted by Piper Jaffray and held in partnership with Cowen and Company is the only investor conference specifically focused on cell and gene therapies, offering exclusive access to the field's most promising companies.

The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Fifth Annual Cell & Gene Therapy Investor Day

2017-02-02 marketwired
This one-day program taking place April 27 is the only investor conference specifically focused on cell and gene therapies, providing institutional, strategic and venture investors with access to 30+ of the field's most promising companies

Bone Therapeutics Taps a New CEO, Drops Plan to Initiate Cell Therapy Trial in the U.S.

2016-11-08 biospace
Thomas Lienard, Chief Executive Officer, and Wim Goemaere, Chief Financial Officer, will host a conference call today at 14:00 CET / 13:00 BST / 08:00 EDT.

Bone Therapeutics's Longtime CEO to Step Down for Personal Reasons

2016-10-11 devicespace
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in bone fracture repair, fracture prevention and spinal fusion, today announces that Enrico Bastianelli has informed the Board of his intention to stand down as Chief Executive Officer after 10 years in the role for personal reasons. Thomas Lienard, the current Chief Business Officer, will become Interim CEO of the Company, working closely with Wim Goemaere, Chief Financial Officer, and the rest of the management team.

Bone Therapeutics CEO to Step Down for Personal Reasons

2016-10-11 biospace
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in bone fracture repair, fracture prevention and spinal fusion, today announces that Enrico Bastianelli has informed the Board of his intention to stand down as Chief Executive Officer after 10 years in the role for personal reasons. Thomas Lienard, the current Chief Business Officer, will become Interim CEO of the Company, working closely with Wim Goemaere, Chief Financial Officer, and the rest of the management team.

Bone Up On First Osteoporosis Data

2016-09-18 seekingalpha
The first data on Bone Therapeutics’ (OTC:BNZPF) cell therapy Preob in severe osteoporosis, showing that the cells accumulate in the bone as hoped, is the initial step towards showing that it can actually spur bone growth.

iSTAR Medical Strengthens Board With Two Senior Appointments

2016-06-28 prnewswire
iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the appointment of Martin Wax, M.D. and Marc Nolet de Brauwere to the Board of Directors.

Is It Time To Invest In Stem Cell Biotechs?

2016-06-03 seekingalpha
Stem cell therapies hold the promise to cure chronic diseases that currently cause a heavy economic burden on society but clinical development has been decades in the making.